Classic EBMT Risk Score Calculator
Estimate the classic European Society for Blood and Marrow Transplantation (EBMT) risk score for allogeneic hematopoietic cell transplantation using 5 historical variables.
- Age: <20 (0), 20-40 (1), >40 (2)
- Disease stage: Early (0), Intermediate (1), Advanced (2)
- Diagnosis to transplant: ≤12 months (0), >12 months (1)
- Donor type: HLA-identical sibling (0), unrelated/other (1)
- Sex combination: Female donor to male recipient (1), all others (0)
Educational use only. This tool does not replace clinical judgment, transplant-board discussion, or institution-specific prognostic models.
What is the EBMT risk score?
The EBMT risk score is a classic clinical risk stratification tool developed from allogeneic stem cell transplant data. It combines five pre-transplant factors into a simple point system (0 to 7 total points). The higher the score, the higher the historical risk profile.
In practice, this score is often used as a quick way to summarize baseline transplant risk before discussing expected outcomes, comparing patient cohorts, or framing treatment planning conversations. It is commonly referred to as the Gratwohl score in older literature.
Variables included in the classic EBMT model
1) Age at transplant
- <20 years: 0 points
- 20-40 years: 1 point
- >40 years: 2 points
2) Disease stage
- Early stage: 0 points
- Intermediate stage: 1 point
- Advanced stage: 2 points
3) Interval from diagnosis to transplant
- ≤12 months: 0 points
- >12 months: 1 point
4) Donor type
- HLA-identical sibling donor: 0 points
- Unrelated donor or other donor setting: 1 point
5) Donor-recipient sex combination
- Female donor to male recipient: 1 point
- All other combinations: 0 points
How to interpret your score
A practical way to interpret totals is by grouping scores into broad risk strata:
- 0-2 points: Lower historical risk profile
- 3-4 points: Intermediate historical risk profile
- 5-7 points: Higher historical risk profile
These categories are useful for orientation, but they are not deterministic predictions for any individual patient. Modern supportive care, graft source strategies, molecular disease risk, MRD status, conditioning intensity, and center-specific protocols can all materially change real-world outcomes.
Why this score still matters (and where it falls short)
Why it remains useful
- Simple and fast bedside summary of baseline allogeneic transplant risk
- Helpful for cohort comparisons and registry-style reporting
- Easy to teach and communicate across teams
Key limitations
- Developed from historical eras; contemporary outcomes may differ significantly
- Does not include genomic or molecular disease risk details
- Does not include comorbidity burden (for example, HCT-CI)
- Does not include donor-specific antibody information, MRD, or performance metrics in detail
Example calculation
Suppose a 46-year-old recipient with intermediate-stage disease undergoes transplant 14 months after diagnosis from an unrelated donor, with a male recipient and female donor combination.
- Age >40: 2 points
- Intermediate stage: 1 point
- Diagnosis to transplant >12 months: 1 point
- Unrelated donor: 1 point
- Female donor to male recipient: 1 point
Total = 6 points, which falls in a higher historical risk category.
Clinical use tips
- Use this as a baseline risk language tool, not a standalone decision engine.
- Pair it with disease-specific risk systems and transplant comorbidity indices.
- Discuss results in multidisciplinary transplant conference context.
- Reassess risk with contemporary center-level outcome data whenever possible.
Bottom line
The EBMT score remains one of the most practical frameworks for quick pre-transplant risk framing in allogeneic hematopoietic cell transplantation. This calculator gives you a fast, transparent way to compute the classic score. For real decisions, always combine it with current evidence, disease biology, and expert transplant-team judgment.